FDA Pharmaceutical and Medical Device Headline NewsExperts: Use Traditional Marketing as a Guide for Social Media PolicyCompanies drafting a social media policy in anticipation of upcoming FDA guidance should try to follow the same general guidelines used for traditional marketing materials, experts advise.Read More
FDA Warns Chinese Devicemaker, Citing Lack of CAPA TriggersThe FDA has warned GRI Medical & Electronic Technology for corrective and preventive action (CAPA) shortfalls and its handling of nonconforming product.Read More
Biotest Recalls Biologic Drug Due to ParticlesJust two months after its first commercial sale, Biotest Pharmaceuticals has voluntarily recalled one lot of its immunodeficiency drug Bivigam due to visible particles.Read More
GOP Track-and-Trace Bill Moves to House Floor Without Unit-Level DesignsA House committee on Wednesday advanced legislation establishing a national track-and-trace system for pharmaceuticals despite vociferous Democratic objections over the bill’s immediate preemption of state laws and lack of a clear unit-level pedigree roadmap.Read More
Draft EMA Guideline Sets Biosimilar Groundwork, Clinical Study ComparisonsThe European Medicines Agency (EMA) on May 2 published draft guidelines aimed at facilitating global development of biosimilars and avoiding unnecessary repeats of clinical trials.Read More
Report Pokes Holes in FDA Celexa Dose WarningThe FDA’s 2011 about-face on Forest Laboratories’ antidepressant Celexa, in which the agency warned against taking the drug at doses higher than previously approved, is being challenged by a group of researchers who say the warning may do more harm than good.Read More
Standardized Device Labeling Still an Undefined Concept: StakeholdersDesigning device labeling that customers will use remains a challenge due to the lack of any standardized terminology and framework, stakeholders at a recent two-day FDA workshop said.Read More
China Considering Fast-Track Pathway for Novel Medical TechnologiesThe China Food and Drug Administration (CFDA) has drafted two measures aimed at expediting approval processes for medical devices. Read More
Sanofi Fined for Discouraging Generic Plavix PrescriptionsFrench drugmaker Sanofi-Aventis was fined $52.6 million by the French competition authority Tuesday for marketing practices that discouraged sales of generic versions of the company’s blood thinner Plavix.Read More
CHMP Backs Bone Drug Restrictions, EU Bans Tetrazepam MedicinesActing on fresh health-risk assessments, the European Medicines Agency’s pharmacovigilance panel is calling for an EU-wide suspension of tetrazepam-containing drugs and recommending new restrictions on the use of a pair of French-made osteoporosis drugs.Read More
FDA Seeks Input on 2014 Generics Regulatory Science PlanIndustry stakeholders will have an opportunity to shape the FDA’s fiscal 2014 regulatory science roadmap for generic drugs during a June 21 public meeting at the agency’s headquarters.Read More
Medtronic Appeals $73.5M Edwards Patent Win to Supreme CourtMedtronic has asked the Supreme Court to hear an appeal in a $73.5 million patent infringement judgment against the company won by Edwards LifeSciences.Read More
IVD Makers Face ‘Quantum Leap’ in Requirements Under Proposed EU RegIn vitro diagnostic manufacturers can expect a “quantum leap” in regulatory burden if the European Commission’s proposed IVD regulation is adopted — a 180-degree turn in notified body requirements, a device legal expert says.Read More
DOJ Submits 11th-Hour Appeal of N.Y. Judge’s Plan B RulingThe White House Monday sought to block a lower court judge’s order requiring the FDA to remove all age restrictions from the emergency contraceptive known as Plan B One-Step.Read More
FDA Inspection Flap Prompts Alexion Risk Assessment ReformAlexion is reviewing its analytical methodologies and procedures to ensure its risk assessments meet the FDA’s expectations, the drugmaker said. Read More
EU: Rapporteur’s Call for Premarket Procedure Draws Industry IreThe European Commission should specify provisions for inspecting clinical trials of in vitro diagnostic devices and not leave oversight to the discretion of EU member states, a draft report by a member of Parliament says.Read More
EU: Include Variations When Submitting Marketing Authorization AmendmentsThe European Medicines Agency released a first revision of good pharmacovigilance practice guideline, adding practical instructions for the application, description and maintenance of the EU reference date list in — and amendments to — marketing authorizations.Read More
Devicemakers Must ‘Act Now’ on Objections to EU Device RegulationsDevicemakers that want their voices heard as the European Parliament considers reforms to medical device regulation need to speak up immediately, experts urge.Read More
DOJ’s Plan B Stay Request Denied; Judge Sets Noon DeadlineA federal judge Friday declined the Obama administration’s request to issue a stay pending appeal of his decision that would lift age and identification restrictions on Teva’s OTC emergency contraceptive Plan B One-Step.Read More
Rise in Global Trial Recruitment Raises Ethics, Compliance Concerns in EUA growing number of pivotal clinical trials — typically Phase III studies — submitted in support of drug applications in Europe are being conducted outside the region, a European Medicines Agency report finds.Read More
Preliminary EMA Changes Announced in Agency Reorganization Shake UpTo improve engagement between the European Medicines Agency, drugmakers and scientific committees, the agency is putting in motion planned changes discussed late last year.Read More
FDA Misses UDI Final Rule Deadline; Hamburg Asked for UpdateThe FDA’s failure to release a final rule on unique device identification by last week’s deadline could delay efforts by other branches of government to put UDIs into use, according to lawmakers.Read More
IMDRF Unveils Global UDI Scheme; Core Concepts Endorsed in EU RecommendationThe International Medical Device Regulators Forum last month unveiled its long-awaited plan for device identification, pushing for a “highly interoperable” and harmonized system to globally track medical devices. Read More
Compounders Counter FDA Call for More Inspection AuthorityCDER Director Janet Woodcock, appearing before a Senate panel Thursday, reiterated the FDA’s call for enhanced authority to seize compounding pharmacy records.Read More
EU Stakeholders Preparing Blueprints on Orphan Drug Access, TransparencyImproved transparency and better access to biosimilars and orphan drugs are key goals in an emerging blueprint for industry being developed by a panel of European pharma stakeholders.Read More
FDA Gives Electronic FARs a Test RunIn an effort to reduce filing errors, the FDA has launched a pilot program for the electronic submission of field alert reports (FARs) using the XML data format.Read More
CareFusion Reaches $41M Agreement Over Sales, Marketing AllegationsCareFusion has reached an agreement in principle to pay the government $41 million, resolving investigations into sales and marketing of its ChloraPrep skin preparation.Read More
U.S. Appeals Court Set to Hear Case Against SEC’s Conflict Minerals Disclosure RuleOral arguments are set for May 15 in a suit pending in the D.C. Circuit Court of Appeals that seeks to overturn the U.S. Securities & Exchange Commission’s (SEC) conflict minerals disclosure requirement.Read More
Speech Therapy Devicemakers Warned Over Quality System ShortfallsThe FDA has warned two makers of speech therapy devices for quality system issues, as well as for lacking device approvals or clearances.Read More
Report on EU IVD Regulation Calls for Stricter Controls Over Clinical Trials, Genetic TestingThe European Commission should specify provisions for inspecting clinical trials of in vitro diagnostic devices and not leave oversight to the discretion of EU member states, a draft report by a member of Parliament says.Read More
FDA Finds Complaint Handling Mistakes at Mattress MakerSCM True Air Technologies, a maker of therapeutic mattresses, fielded a four-observation Form 483 related to its handling of complaints and manufacturing changes.Read More
Gamechanger: FDA Tests Counterfeit Detection DeviceThe FDA plans to test a device in Ghana in 2013 and 2014 that it hopes will root out counterfeit and substandard antimalarial drugs. Read More
Potential Xyrem REMS Changes Could Invite GenericsJazz Pharmaceuticals told investors Monday it expects the FDA to require modifications to the current risk evaluation and mitigation strategy (REMS) for its highly controlled narcolepsy drug Xyrem, a move some analysts say could expand market opportunities for generic competitors.Read More
EMA’s Move to Increase Transparency Muddied Following Interim Court OrderThe General Court of the European Union has issued a temporary injunction barring the European Medicines Agency (EMA) from releasing information on clinical data.Read More
FDA Issues Safety Alerts on Botox, Hospira and PotigaOver the past two weeks, the FDA has issued a flurry of safety alerts to warn the public of problems with different drugs, including adverse events tied to the anti-seizure drug Potiga, fake Botox and fleck-infused containers of injectable drugs produced by Hospira.Read More
|